Placebo matching ALXN2040 clinical trials

A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This study is looking at a new medicine called Danicopan for a type of age-related macular degeneration (AMD) called geographic atrophy (GA). Researchers want to see if the medicine can slow down vision loss and the growth of blind spots.